First children to receive new 'Living Drug' for tough cancers
NCT ID NCT07358260
Summary
This is a first-in-human study to test the safety and find the right dose of a new cell therapy for children and young adults whose solid tumors have returned or stopped responding to standard treatments. The therapy, called B7-H3 CAR T cells, uses a patient's own modified immune cells to target a specific protein found on many pediatric cancers. The study will enroll up to 40 participants at a single center.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institite
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.